Lansoprazole shares class safety considerations with other PPIs; confirm hypersensitivity and ensure ongoing therapy remains clinically indicated.
Absolute contraindications include hypersensitivity to lansoprazole and concomitant use with rilpivirine. Relative precautions involve prolonged therapy, hepatic impairment, hypomagnesemia, and interactions with drugs that require acidic pH for absorption.
Documented hypersensitivity to lansoprazole or other substituted benzimidazole proton pump inhibitors
Concomitant use with rilpivirine-containing antiretroviral products
Long-term therapy without periodic reassessment—monitor for C. difficile infection and nutrient deficiencies
History of hypomagnesemia or concurrent diuretics—check electrolytes during prolonged therapy
Severe hepatic impairment—reduce maintenance dose and monitor liver function
Medications requiring acidic gastric pH for absorption (atazanavir, ketoconazole, itraconazole)—consider alternatives
High fracture risk or osteoporosis—chronic PPI use may decrease calcium absorption